Janne Estill1, Nathan Ford2, Luisa Salazar-Vizcaya3, Andreas D Haas3, Nello Blaser3, Vincent Habiyambere2, Olivia Keiser3. 1. University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland. Electronic address: janne.estill@ispm.unibe.ch. 2. World Health Organization, Department of HIV/AIDS, Geneva, Switzerland. 3. University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland.
Abstract
BACKGROUND: The number of patients in need of second-line antiretroviral drugs is increasing in sub-Saharan Africa. We aimed to project the need of second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030. METHODS: We developed a simulation model for HIV and applied it to each sub-Saharan African country. We used the WHO country intelligence database to estimate the number of adult patients receiving antiretroviral therapy from 2005 to 2014. We fitted the number of adult patients receiving antiretroviral therapy to observed estimates, and predicted first-line and second-line needs between 2015 and 2030. We present results for sub-Saharan Africa, and eight selected countries. We present 18 scenarios, combining the availability of viral load monitoring, speed of antiretroviral scale-up, and rates of retention and switching to second-line. HIV transmission was not included. FINDINGS: Depending on the scenario, 8·7-25·6 million people are expected to receive antiretroviral therapy in 2020, of whom 0·5-3·0 million will be receiving second-line antiretroviral therapy. The proportion of patients on treatment receiving second-line therapy was highest (15·6%) in the scenario with perfect retention and immediate switching, no further scale-up, and universal routine viral load monitoring. In 2030, the estimated range of patients receiving antiretroviral therapy will remain constant, but the number of patients receiving second-line antiretroviral therapy will increase to 0·8-4·6 million (6·6-19·6%). The need for second-line antiretroviral therapy was two to three times higher if routine viral load monitoring was implemented throughout the region, compared with a scenario of no further viral load monitoring scale-up. For each monitoring strategy, the future proportion of patients receiving second-line antiretroviral therapy differed only minimally between countries. INTERPRETATION: Donors and countries in sub-Saharan Africa should prepare for a substantial increase in the need for second-line drugs during the next few years as access to viral load monitoring improves. An urgent need exists to decrease the costs of second-line drugs. FUNDING: World Health Organization, Swiss National Science Foundation, National Institutes of Health.
BACKGROUND: The number of patients in need of second-line antiretroviral drugs is increasing in sub-Saharan Africa. We aimed to project the need of second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030. METHODS: We developed a simulation model for HIV and applied it to each sub-Saharan African country. We used the WHO country intelligence database to estimate the number of adult patients receiving antiretroviral therapy from 2005 to 2014. We fitted the number of adult patients receiving antiretroviral therapy to observed estimates, and predicted first-line and second-line needs between 2015 and 2030. We present results for sub-Saharan Africa, and eight selected countries. We present 18 scenarios, combining the availability of viral load monitoring, speed of antiretroviral scale-up, and rates of retention and switching to second-line. HIV transmission was not included. FINDINGS: Depending on the scenario, 8·7-25·6 million people are expected to receive antiretroviral therapy in 2020, of whom 0·5-3·0 million will be receiving second-line antiretroviral therapy. The proportion of patients on treatment receiving second-line therapy was highest (15·6%) in the scenario with perfect retention and immediate switching, no further scale-up, and universal routine viral load monitoring. In 2030, the estimated range of patients receiving antiretroviral therapy will remain constant, but the number of patients receiving second-line antiretroviral therapy will increase to 0·8-4·6 million (6·6-19·6%). The need for second-line antiretroviral therapy was two to three times higher if routine viral load monitoring was implemented throughout the region, compared with a scenario of no further viral load monitoring scale-up. For each monitoring strategy, the future proportion of patients receiving second-line antiretroviral therapy differed only minimally between countries. INTERPRETATION: Donors and countries in sub-Saharan Africa should prepare for a substantial increase in the need for second-line drugs during the next few years as access to viral load monitoring improves. An urgent need exists to decrease the costs of second-line drugs. FUNDING: World Health Organization, Swiss National Science Foundation, National Institutes of Health.
Authors: Luisa Salazar-Vizcaya; Olivia Keiser; Mary-Ann Davies; Andreas D Haas; Nello Blaser; Vivian Cox; Brian Eley; Helena Rabie; Harry Moultrie; Janet Giddy; Robin Wood; Matthias Egger; Janne Estill Journal: AIDS Date: 2014-10-23 Impact factor: 4.177
Authors: Janne Estill; Cindy Aubrière; Matthias Egger; Leigh Johnson; Robin Wood; Daniela Garone; Thomas Gsponer; Gilles Wandeler; Andrew Boulle; Mary-Ann Davies; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger Journal: Lancet HIV Date: 2015-06-16 Impact factor: 12.767
Authors: Rashida A Ferrand; Elizabeth L Corbett; Robin Wood; John Hargrove; Chiratidzo E Ndhlovu; Frances M Cowan; Eleanor Gouws; Brian G Williams Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: Janne Estill; Matthias Egger; Nello Blaser; Luisa Salazar Vizcaya; Daniela Garone; Robin Wood; Jennifer Campbell; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Victor Musiime; Elizabeth Kaudha; Joshua Kayiwa; Grace Mirembe; Matthew Odera; Hilda Kizito; Immaculate Nankya; Francis Ssali; Cissy Kityo; Robert Colebunders; Peter Mugyenyi Journal: AIDS Res Hum Retroviruses Date: 2013-01-11 Impact factor: 2.205
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer Journal: PLoS Med Date: 2015-04-07 Impact factor: 11.069
Authors: Janne Estill; Matthias Egger; Leigh F Johnson; Thomas Gsponer; Gilles Wandeler; Mary-Ann Davies; Andrew Boulle; Robin Wood; Daniela Garone; Jeffrey S A Stringer; Timothy B Hallett; Olivia Keiser Journal: PLoS One Date: 2013-02-28 Impact factor: 3.240
Authors: Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Man Po Lee; Cuong Duy Do; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: AIDS Care Date: 2017-01-29
Authors: Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771
Authors: Katherine A Sutherland; Dami A Collier; Daniel T Claiborne; Jessica L Prince; Martin J Deymier; Richard A Goldstein; Eric Hunter; Ravindra K Gupta Journal: Sci Rep Date: 2016-11-30 Impact factor: 4.379
Authors: Nicole K Le; Emilia Riggi; Gaetano Marrone; Tam Van Vu; Ricardo O Izurieta; Chuc Kim Thi Nguyen; Mattias Larsson; Cuong Duy Do Journal: PLoS One Date: 2017-09-06 Impact factor: 3.240